阻断CTLA-4通过激活Th17细胞促进压力过载引起的心力衰竭
An-Qi Shang1, Chang-Jiang Yu2, Xin Bi1
1Departments of Cardiology and Critical Care Medicine, NHC Key Laboratory of Cell Transplantation, Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
概括
抗细胞毒性T-淋巴细胞相关抗原-4 (CTLA-4) 抗体通过促进T辅助17 (Th17) 细胞分化,在小鼠中恶化心力衰竭. 准CXCR4/Th17/IL-17A通路可能会防止免疫检查点抑制剂心脏毒性.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 免疫检查点抑制剂,如抗CTLA-4抗体,在癌症免疫治疗中具有好处,但可能导致心脏不良影响.
- 压力过载模型,如横向大动脉收缩 (TAC),诱导心脏重塑和心力衰竭.
研究的目的:
- 研究抗CTLA-4抗体对压力过载引起的心脏重塑和功能障碍的影响.
- 阐明抗CTLA-4抗体介导心脏毒性的潜在机制.
主要方法:
- 小鼠接受了TAC,以诱导心脏缩和心力衰竭.
- 给予抗CTLA-4抗体,随后对心脏功能,组织学和免疫细胞概况进行评估.
- 干预措施包括抗IL-17A抗体和CXCR4对手AMD3100.
主要成果:
- 抗CTLA-4抗体加剧了TAC诱导的心脏功能障碍,过度缩小和纤维化.
- 观察到系统性炎症因子升高和T助手17 (Th17) 细胞分化增加.
- 抑制IL-17A或CXCR4可以逆转心脏毒性影响.
结论:
- 抗CTLA-4抗体的使用会通过Th17细胞的激活和分化,使压力过载引起的心力衰竭恶化.
- 准CXCR4/Th17/IL-17A轴是一个潜在的策略,可以减轻免疫检查点抑制剂引起的心脏毒性.
相关概念视频
T Cell Types and Functions
966
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
966
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Antihypertensive Drugs: Action of β1 Blockers
381
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
381
Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326


